In silico and cheminformatics prediction with experimental validation of an adipogenesis cocktail, sorafenib with rosiglitazone for HCC dedifferentiation

Purpose: Hepatocellular carcinoma (HCC) resistance to sorafenib treatment and other treatment strategies causes a higher mortality rate in patients diagnosed with HCC.Research question.HCC often develops resistance to sorafenib treatment and other therapies, leading to increased mortality rates in d...

Descripció completa

Dades bibliogràfiques

Autors principals:	Aya Anis, Ahmed M. Mostafa, Mariam S. Kerema, Nadia M. Hamdy, Ahmed S. Sultan
Format:	Artigo
Idioma:	Inglês
Publicat:	Elsevier 2024-12-01
Col·lecció:	Journal of Genetic Engineering and Biotechnology
Matèries:	Rosiglitazone Insulin IBMX, PPARγ HCC Sorafenib Adipogenesis-inducer
Accés en línia:	http://www.sciencedirect.com/science/article/pii/S1687157X2400132X
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!